Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions

Gregory J. Kato, Robert P. Hebbel, Martin H. Steinberg, Mark T. Gladwin

Research output: Contribution to journalArticle

Abstract

Sickle cell disease has been very well characterized as a single amino acid molecular disorder of hemoglobin leading to its pathological polymerization, with resulting red cell rigidity that causes poor microvascular blood flow, with consequent tissue ischemia and infarction. More recently, an independent spectrum of pathophysiology of blood vessel function has been demonstrated, involving abnormal vascular tone and activated, adhesive endothelium. These vasculopathic abnormalities are attributable to pathways involving hemolysis-associated defects in nitric oxide bioavailability, oxidative stress, ischemia-reperfusion injury, hemostatic activation, leukocytes and platelets. Vasculopathy of sickle cell disease has been implicated in the development of pulmonary hypertension, stroke, leg ulceration and priapism, particularly associated with hemolytic severity, and reported also in other severe hemolytic disorders. This vasculopathy might also play a role in other chronic organ dysfunction in patients with sickle cell disease. These pathways present novel targets for pharmacologic intervention, and several clinical trials are already under way. The authors present their perspectives of a workshop held at the National Institutes of Health in August 2008 on vasculopathy in sickle cell disease, along with meritorious future scientific questions on the topic of vascular complications of sickle cell disease.

Original languageEnglish (US)
Pages (from-to)618-625
Number of pages8
JournalAmerican Journal of Hematology
Volume84
Issue number9
DOIs
StatePublished - Sep 2009
Externally publishedYes

Fingerprint

Translational Medical Research
Sickle Cell Anemia
Cell Biology
Blood Vessels
Research
Priapism
Platelet Activation
National Institutes of Health (U.S.)
Hemostatics
Hemolysis
Reperfusion Injury
Pulmonary Hypertension
Polymerization
Adhesives
Infarction
Biological Availability
Endothelium
Leg
Nitric Oxide
Hemoglobins

ASJC Scopus subject areas

  • Hematology

Cite this

Vasculopathy in sickle cell disease : Biology, pathophysiology, genetics, translational medicine, and new research directions. / Kato, Gregory J.; Hebbel, Robert P.; Steinberg, Martin H.; Gladwin, Mark T.

In: American Journal of Hematology, Vol. 84, No. 9, 09.2009, p. 618-625.

Research output: Contribution to journalArticle

Kato, Gregory J. ; Hebbel, Robert P. ; Steinberg, Martin H. ; Gladwin, Mark T. / Vasculopathy in sickle cell disease : Biology, pathophysiology, genetics, translational medicine, and new research directions. In: American Journal of Hematology. 2009 ; Vol. 84, No. 9. pp. 618-625.
@article{d575f30e585c41f3b6bb9b1b4e7361c4,
title = "Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions",
abstract = "Sickle cell disease has been very well characterized as a single amino acid molecular disorder of hemoglobin leading to its pathological polymerization, with resulting red cell rigidity that causes poor microvascular blood flow, with consequent tissue ischemia and infarction. More recently, an independent spectrum of pathophysiology of blood vessel function has been demonstrated, involving abnormal vascular tone and activated, adhesive endothelium. These vasculopathic abnormalities are attributable to pathways involving hemolysis-associated defects in nitric oxide bioavailability, oxidative stress, ischemia-reperfusion injury, hemostatic activation, leukocytes and platelets. Vasculopathy of sickle cell disease has been implicated in the development of pulmonary hypertension, stroke, leg ulceration and priapism, particularly associated with hemolytic severity, and reported also in other severe hemolytic disorders. This vasculopathy might also play a role in other chronic organ dysfunction in patients with sickle cell disease. These pathways present novel targets for pharmacologic intervention, and several clinical trials are already under way. The authors present their perspectives of a workshop held at the National Institutes of Health in August 2008 on vasculopathy in sickle cell disease, along with meritorious future scientific questions on the topic of vascular complications of sickle cell disease.",
author = "Kato, {Gregory J.} and Hebbel, {Robert P.} and Steinberg, {Martin H.} and Gladwin, {Mark T.}",
year = "2009",
month = "9",
doi = "10.1002/ajh.21475",
language = "English (US)",
volume = "84",
pages = "618--625",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Vasculopathy in sickle cell disease

T2 - Biology, pathophysiology, genetics, translational medicine, and new research directions

AU - Kato, Gregory J.

AU - Hebbel, Robert P.

AU - Steinberg, Martin H.

AU - Gladwin, Mark T.

PY - 2009/9

Y1 - 2009/9

N2 - Sickle cell disease has been very well characterized as a single amino acid molecular disorder of hemoglobin leading to its pathological polymerization, with resulting red cell rigidity that causes poor microvascular blood flow, with consequent tissue ischemia and infarction. More recently, an independent spectrum of pathophysiology of blood vessel function has been demonstrated, involving abnormal vascular tone and activated, adhesive endothelium. These vasculopathic abnormalities are attributable to pathways involving hemolysis-associated defects in nitric oxide bioavailability, oxidative stress, ischemia-reperfusion injury, hemostatic activation, leukocytes and platelets. Vasculopathy of sickle cell disease has been implicated in the development of pulmonary hypertension, stroke, leg ulceration and priapism, particularly associated with hemolytic severity, and reported also in other severe hemolytic disorders. This vasculopathy might also play a role in other chronic organ dysfunction in patients with sickle cell disease. These pathways present novel targets for pharmacologic intervention, and several clinical trials are already under way. The authors present their perspectives of a workshop held at the National Institutes of Health in August 2008 on vasculopathy in sickle cell disease, along with meritorious future scientific questions on the topic of vascular complications of sickle cell disease.

AB - Sickle cell disease has been very well characterized as a single amino acid molecular disorder of hemoglobin leading to its pathological polymerization, with resulting red cell rigidity that causes poor microvascular blood flow, with consequent tissue ischemia and infarction. More recently, an independent spectrum of pathophysiology of blood vessel function has been demonstrated, involving abnormal vascular tone and activated, adhesive endothelium. These vasculopathic abnormalities are attributable to pathways involving hemolysis-associated defects in nitric oxide bioavailability, oxidative stress, ischemia-reperfusion injury, hemostatic activation, leukocytes and platelets. Vasculopathy of sickle cell disease has been implicated in the development of pulmonary hypertension, stroke, leg ulceration and priapism, particularly associated with hemolytic severity, and reported also in other severe hemolytic disorders. This vasculopathy might also play a role in other chronic organ dysfunction in patients with sickle cell disease. These pathways present novel targets for pharmacologic intervention, and several clinical trials are already under way. The authors present their perspectives of a workshop held at the National Institutes of Health in August 2008 on vasculopathy in sickle cell disease, along with meritorious future scientific questions on the topic of vascular complications of sickle cell disease.

UR - http://www.scopus.com/inward/record.url?scp=69549107429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69549107429&partnerID=8YFLogxK

U2 - 10.1002/ajh.21475

DO - 10.1002/ajh.21475

M3 - Article

C2 - 19610078

AN - SCOPUS:69549107429

VL - 84

SP - 618

EP - 625

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 9

ER -